Endocrinological, immunological and metabolic features of patients with Fabry disease under therapy

J Pediatr Endocrinol Metab. 2023 May 31;0(0):650-658. doi: 10.1515/jpem-2023-0105. Print 2023 Jul 26.

Abstract

Objectives: Fabry disease is an X-linked lysosomal disorder caused by decreased or absent alpha galactosidase enzyme. The enzyme deficiency leads to progressive accumulation of globotriaosylceramide (Gb-3) and its deacetylated form lyso-Gb3 in various tissue lysosomes that results in primarily lysosomal deterioration and subsequently mitochondrial, endothelial, and immunologic dysfunctions.

Methods: The endocrinological, metabolic, immunological and HLA status of 12 patients were evaluated.

Results: A total of 11 patients (91.6 %) had immunologic and/or endocrinologic abnormalities. fT4, anti-TPO, and anti-TG levels were increased in 1, 2, and 2 patients, respectively. Three patients had elevated proinflammatory cytokines. ANA profile, p-ANCA and c-ANCA were positive in 1, 1, and 2 patients, respectively. Tissue transglutaminase antibody was negative in all patients however P5 was diagnosed with Celiac disease at the age of 12 and on gluten free diet. All patients had distinct types of HLA apart from 2 patients with anti-TG and anti-TPO positive and there was no relationship between the HLA types and the autoimmunity biomarkers.

Conclusions: FD may have impact on endocrinologic and immunologic abnormalities even in the patients under ERT, therefore prevalence of these abnormalities may be higher in ERT naïve patients. However, apparently, they are less likely to cause clinical symptoms. Certain HLA alleles may contribute to the direct impact of immunological pathogenesis in FD by developing abnormal autoimmune biomarkers. To the best of our knowledge, this is the first study investigating HLA status of FD patients; therefore further studies are needed to elucidate the underlying mechanism of action.

Keywords: Fabry disease; endocrinopathy; hla typing; immunopathy.

MeSH terms

  • Biomarkers
  • Endocrinology*
  • Enzyme Replacement Therapy
  • Fabry Disease* / pathology
  • Humans
  • alpha-Galactosidase

Substances

  • alpha-Galactosidase
  • Biomarkers